ARTICLE | Company News
Marina Biotech, ProNAi deal
March 19, 2012 7:00 AM UTC
ProNAi partnered with Marina to use Marina's Smarticles liposomal delivery technology to develop single-strand oligonucleotides to treat cancer through DNA interference (DNAi). Marina is eligible to receive up to $14 million per gene target in total upfront and milestone payments, plus royalties. ProNAi has the option to select any number of additional targets. Marina acquired the Smarticles technology from novosom AG (Halle, Germany) in 2010 (see BioCentury, Aug. 2, 2010). ...